
|Videos|October 17, 2016
Actionable Mutations Impacting Breast Cancer Treatment
Author(s)Erin Wysong Hofstatter, MD
Erin Wysong Hofstatter, MD, associate professor at Yale Cancer Center and co-director of the Cancer Genetics and Prevention Program, discusses the actionable mutations that impact treatment and surgical decisions in breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































